TIBER CREEK GROUP for PHRMA
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; Issues related to capping out of pocket costs; S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Consolidated Appropriations Act, 2023 (PL 117-328), Division FF, Title III - Food and Drug Administration, Subtitle B - Drugs and Biologics and Subtitle F, Chapter 1 - Clinical Trial Diversity and Modernization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| COREY MALMGREN | — |
Medicare/Medicaid MMM
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| COREY MALMGREN | — |
Trade (domestic/foreign) TRD
Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| COREY MALMGREN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.